SH3YL1 and urinary bladder carcinoma: Given cisplatin’s dual impact as both an antitumor agent and a nephrotoxin, understanding SH3YL1’s behavior in bladder cancer patients undergoing cisplatin therapy could reveal its potential as a biomarker for both tumor progression and renal injury.